Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).